Moody Lynn & Lieberson LLC cut its position in Boston Scientific Corporation (NYSE:BSX) by 43.8% in the third quarter, according to the company in its most recent disclosure with the Securities and Exchange Commission (SEC). The institutional investor owned 75,340 shares of the medical equipment provider’s stock after selling 58,671 shares during the period. Moody Lynn & Lieberson LLC’s holdings in Boston Scientific Corporation were worth $2,198,000 as of its most recent filing with the Securities and Exchange Commission (SEC).

Several other hedge funds and other institutional investors have also recently made changes to their positions in the company. Swiss National Bank boosted its position in shares of Boston Scientific Corporation by 2.9% during the second quarter. Swiss National Bank now owns 5,584,930 shares of the medical equipment provider’s stock worth $154,814,000 after acquiring an additional 156,800 shares during the last quarter. Wells Fargo & Company MN boosted its position in shares of Boston Scientific Corporation by 10.5% during the second quarter. Wells Fargo & Company MN now owns 9,157,768 shares of the medical equipment provider’s stock worth $253,854,000 after acquiring an additional 867,983 shares during the last quarter. Sit Investment Associates Inc. boosted its position in shares of Boston Scientific Corporation by 37.8% during the third quarter. Sit Investment Associates Inc. now owns 141,710 shares of the medical equipment provider’s stock worth $4,134,000 after acquiring an additional 38,855 shares during the last quarter. Los Angeles Capital Management & Equity Research Inc. boosted its position in shares of Boston Scientific Corporation by 35,016.2% during the second quarter. Los Angeles Capital Management & Equity Research Inc. now owns 3,042,464 shares of the medical equipment provider’s stock worth $84,337,000 after acquiring an additional 3,033,800 shares during the last quarter. Finally, LS Investment Advisors LLC boosted its position in shares of Boston Scientific Corporation by 5.8% during the third quarter. LS Investment Advisors LLC now owns 40,621 shares of the medical equipment provider’s stock worth $1,185,000 after acquiring an additional 2,209 shares during the last quarter. 90.50% of the stock is owned by hedge funds and other institutional investors.

Boston Scientific Corporation (BSX) traded down $0.23 during midday trading on Monday, reaching $28.36. 6,526,000 shares of the company’s stock were exchanged, compared to its average volume of 6,966,843. The company has a quick ratio of 0.50, a current ratio of 0.72 and a debt-to-equity ratio of 0.58. The stock has a market cap of $38,943.84, a P/E ratio of 23.25, a price-to-earnings-growth ratio of 2.19 and a beta of 1.00. Boston Scientific Corporation has a 1-year low of $19.67 and a 1-year high of $29.93.

Boston Scientific Corporation (NYSE:BSX) last posted its earnings results on Thursday, October 26th. The medical equipment provider reported $0.31 EPS for the quarter, meeting analysts’ consensus estimates of $0.31. The business had revenue of $2.22 billion for the quarter, compared to the consensus estimate of $2.21 billion. Boston Scientific Corporation had a net margin of 9.55% and a return on equity of 23.60%. The company’s revenue for the quarter was up 5.6% on a year-over-year basis. During the same quarter last year, the firm posted $0.27 EPS. equities research analysts expect that Boston Scientific Corporation will post 1.25 earnings per share for the current year.

ILLEGAL ACTIVITY WARNING: This piece of content was first published by The Cerbat Gem and is the sole property of of The Cerbat Gem. If you are accessing this piece of content on another website, it was illegally copied and reposted in violation of U.S. & international trademark and copyright legislation. The correct version of this piece of content can be accessed at https://www.thecerbatgem.com/2017/11/13/moody-lynn-lieberson-llc-has-2-20-million-stake-in-boston-scientific-corporation-bsx.html.

In other news, EVP Timothy A. Pratt sold 10,104 shares of the firm’s stock in a transaction dated Friday, September 1st. The shares were sold at an average price of $27.46, for a total value of $277,455.84. Following the sale, the executive vice president now directly owns 185,742 shares in the company, valued at approximately $5,100,475.32. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which can be accessed through this link. Also, EVP Supratim Bose sold 347,137 shares of the firm’s stock in a transaction dated Wednesday, October 4th. The shares were sold at an average price of $29.12, for a total transaction of $10,108,629.44. The disclosure for this sale can be found here. Insiders sold a total of 508,864 shares of company stock worth $14,581,669 over the last 90 days. Company insiders own 0.74% of the company’s stock.

BSX has been the subject of a number of research reports. Cowen and Company restated an “outperform” rating and set a $31.00 target price on shares of Boston Scientific Corporation in a research report on Monday, July 17th. BidaskClub lowered shares of Boston Scientific Corporation from a “buy” rating to a “hold” rating in a research report on Tuesday, July 25th. Oppenheimer Holdings, Inc. set a $29.00 price objective on shares of Boston Scientific Corporation and gave the company a “hold” rating in a research report on Friday, July 28th. Stifel Nicolaus reiterated a “buy” rating and set a $32.00 price objective on shares of Boston Scientific Corporation in a research report on Sunday, July 30th. Finally, Zacks Investment Research upgraded shares of Boston Scientific Corporation from a “sell” rating to a “hold” rating in a research report on Monday, July 31st. One investment analyst has rated the stock with a sell rating, five have assigned a hold rating, fourteen have issued a buy rating and one has issued a strong buy rating to the company. The company has an average rating of “Buy” and an average price target of $30.77.

About Boston Scientific Corporation

Boston Scientific Corporation is a developer, manufacturer and marketer of medical devices that are used in a range of interventional medical specialties. The Company offers its products by seven businesses: Interventional Cardiology, Cardiac Rhythm Management, Endoscopy, Peripheral Interventions, Urology and Pelvic Health, Neuromodulation, and Electrophysiology.

Want to see what other hedge funds are holding BSX? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Boston Scientific Corporation (NYSE:BSX).

Institutional Ownership by Quarter for Boston Scientific Corporation (NYSE:BSX)

Receive News & Stock Ratings for Boston Scientific Corporation Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Boston Scientific Corporation and related stocks with our FREE daily email newsletter.